Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/hep.26066 http://scihub22266oqcxt.onion/10.1002/hep.26066 22996292!3566288!22996292     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hepatology 2013 ; 57 (2): 461-9 Nephropedia Template TP {{tp|p=22996292|t=2013. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry |pdf=|usr=}}{{22996292}} gab.com Text IFITM1 is a tight junction protein that inhibits hepatitis C virus entry JO: Hepatology http://www.kidney.de/pget.php?&tw=1&pmid=22996292 #FOAvip Type 1 interferon (IFN) continues to be the foundation for the current standard of care combination therapy for chronic hepatitis C virus (HCV) infection, yet the component interferon-stimulated genes (ISGs) that mediate the antiviral actions of IFN are not fully defined. Interferon-induced transmembrane protein 1 (IFITM1) is an ISG product that suppresses early stage infection by a number of viruses through an unknown mechanism of action. Moreover, the actions of IFITM1 on HCV infection are not fully elucidated. Here we identify IFITM1 as a hepatocyte tight junction protein and a potent anti-HCV effector molecule. IFITM1 expression is induced early during IFN treatment of hepatocytes and accumulates at hepatic tight junctions in HCV-infected human patient liver during IFN therapy. Additionally, we found that IFITM1 interacts with HCV coreceptors, including CD81 and occludin, to disrupt the process of viral entry. Thus, IFITM1 is an anti-HCV ISG whose actions impart control of HCV infection through interruption of viral coreceptor function. CONCLUSION: This study defines IFITM1 as an ISG effector with action against HCV entry. Design of therapy regimens to enhance IFITM1 expression should improve the virologic response among HCV patients undergoing treatment with type I IFN. Twit Text FOAVip IFITM1 is a tight junction protein that inhibits hepatitis C virus entry ????Hepatology http://www.kidney.de/pget.php?&tw=1&pmid=22996292 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22996292 #FOAvip English Wikipedia <ref>{{Cite pmid|22996292}}</ref> IFITM1 is a tight junction protein that inhibits hepatitis C virus entry #MMPMID22996292 Wilkins C; Woodward J; Lau DT; Barnes A; Joyce M; McFarlane N; McKeating JA; Tyrrell DL; Gale M Jr Hepatology 2013[Feb]; 57 (2): 461-9 PMID22996292show ga Type 1 interferon (IFN) continues to be the foundation for the current standard of care combination therapy for chronic hepatitis C virus (HCV) infection, yet the component interferon-stimulated genes (ISGs) that mediate the antiviral actions of IFN are not fully defined. Interferon-induced transmembrane protein 1 (IFITM1) is an ISG product that suppresses early stage infection by a number of viruses through an unknown mechanism of action. Moreover, the actions of IFITM1 on HCV infection are not fully elucidated. Here we identify IFITM1 as a hepatocyte tight junction protein and a potent anti-HCV effector molecule. IFITM1 expression is induced early during IFN treatment of hepatocytes and accumulates at hepatic tight junctions in HCV-infected human patient liver during IFN therapy. Additionally, we found that IFITM1 interacts with HCV coreceptors, including CD81 and occludin, to disrupt the process of viral entry. Thus, IFITM1 is an anti-HCV ISG whose actions impart control of HCV infection through interruption of viral coreceptor function. CONCLUSION: This study defines IFITM1 as an ISG effector with action against HCV entry. Design of therapy regimens to enhance IFITM1 expression should improve the virologic response among HCV patients undergoing treatment with type I IFN. |Antigens, Differentiation/biosynthesis/metabolism/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Cells, Cultured[MESH] |Hepacivirus/drug effects/physiology[MESH] |Hepatitis C/*immunology[MESH] |Humans[MESH] |Interferon Type I/*therapeutic use[MESH] |Receptors, Virus/*drug effects[MESH] |Tetraspanin 28/metabolism[MESH] |Tight Junction Proteins/*physiology[MESH]IFITM1 is a tight junction protein that inhibits hepatitis C virus ent(epmc).pdf DeepDyve Pubget Overpricing